Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 4/20 | 0.60 |
| ▸ | AKT2 | P31751 | 4/20 | 0.60 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 11/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071100 | 0.82 | F2RL1 (0.77) | AKT1AKT2F2RL1HPGDCNR1 | |
| SCHEMBL15071143 | 0.81 | F2RL1 (0.74) | AKT1AKT2F2RL1HPGDCNR1 | |
| SCHEMBL361257 | 0.75 | AKT2 (1.00) | AKT1AKT2 | |
| SCHEMBL15071102 | 0.75 | CNR1 (0.49) | AKT1AKT2F2RL1HPGDCNR1 | |
| SCHEMBL31560 | 0.74 | F2RL1 (0.63) | F2RL1HPGDNPC1RAB9AMEN1 | |
| SCHEMBL15071152 | 0.74 | F2RL1 (0.75) | F2RL1HPGDMEN1ALDH1A1KMT2A | |
| SCHEMBL15071136 | 0.73 | F2RL1 (0.62) | F2RL1HPGDNPC1RAB9AMEN1 | |
| SCHEMBL15071132 | 0.73 | F2RL1 (0.64) | F2RL1HPGDCNR1NPC1RAB9A | |
| SCHEMBL15071141 | 0.73 | F2RL1 (0.61) | F2RL1HPGDNPC1RAB9AMEN1 | |
| SCHEMBL15071131 | 0.73 | F2RL1 (0.61) | F2RL1HPGDNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012026765-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | (주)네오팜 (KR) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, FPR2 | AKT1 669/4885AKT2 475/4885F2RL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.